Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Remke

Showing results (111-120 of 184) with videos related to

Pageof 19
Sort By:
Oncotarget|December 22, 2016
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testingFlorian Selt, Juliane Hohloch, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaMarc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Acta Neuropathologica|August 15, 2014
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cellsMark Barszczyk, Pawel Buczkowicz, Pedro Castelo-Branco, et al.
Neuro-Oncology|August 22, 2020
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaJonas Ecker, Venu Thatikonda, Gianluca Sigismondo, et al.
Acta Neuropathologica|May 6, 2014
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohortTorsten Pietsch, Rene Schmidt, Marc Remke, et al.
Acta Neuropathologica|December 14, 2011
Biological and clinical heterogeneity of MYCN-amplified medulloblastomaAndrey Korshunov, Marc Remke, Marcel Kool, et al.
Acta Neuropathologica|April 5, 2016
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
American Journal of Human Genetics|February 1, 2020
Bi-allelic Variants in RALGAPA1 Cause Profound Neurodevelopmental Disability, Muscular Hypotonia, Infantile Spasms, and Feeding AbnormalitiesMatias Wagner, Yuliya Skorobogatko, Ben Pode-Shakked, et al.
Journal of Neuro-Oncology|May 14, 2023
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cellsGintvile Valinciute, Jonas Ecker, Florian Selt, et al.
Hemasphere|April 3, 2025
H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemiaVera H Jepsen, Andrea Hanel, Daniel Picard, et al.
Pageof 19

Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
Oncotarget|December 22, 2016
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testingFlorian Selt, Juliane Hohloch, Thomas Hielscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaMarc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Acta Neuropathologica|August 15, 2014
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cellsMark Barszczyk, Pawel Buczkowicz, Pedro Castelo-Branco, et al.
Neuro-Oncology|August 22, 2020
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastomaJonas Ecker, Venu Thatikonda, Gianluca Sigismondo, et al.
Acta Neuropathologica|May 6, 2014
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohortTorsten Pietsch, Rene Schmidt, Marc Remke, et al.
Acta Neuropathologica|December 14, 2011
Biological and clinical heterogeneity of MYCN-amplified medulloblastomaAndrey Korshunov, Marc Remke, Marcel Kool, et al.
Acta Neuropathologica|April 5, 2016
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
American Journal of Human Genetics|February 1, 2020
Bi-allelic Variants in RALGAPA1 Cause Profound Neurodevelopmental Disability, Muscular Hypotonia, Infantile Spasms, and Feeding AbnormalitiesMatias Wagner, Yuliya Skorobogatko, Ben Pode-Shakked, et al.
Journal of Neuro-Oncology|May 14, 2023
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cellsGintvile Valinciute, Jonas Ecker, Florian Selt, et al.
Hemasphere|April 3, 2025
H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemiaVera H Jepsen, Andrea Hanel, Daniel Picard, et al.
Pageof 19